Loading company
Harvard Apparatus Regenerative Technology, Inc.
HRGN · OTC
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
HRGN · OTC
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $145K | $123K | +17.89% |
| Profit | -$1.5M | -$1.7M | +13.94% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Harvard Apparatus Regenerative Technology, Inc. has no earnings call transcript available.
Inc. Biostage is a clinical-stage biotech company that uses cell therapy to regenerate organs inside the human body to treat cancer, trauma and birth defects in the esophagus and bronchus. We have performed the world’s first regeneration of an esophagus in a human cancer patient. This surgery was performed at Mayo Clinic and was published in August 2021. We have performed the regeneration of the bronchus in a pig. Biostage has 10 issued U.S. patents, 2 orphan-drug designations (which provide 7 years of market exclusivity in addition to any patents), and the possibility of 2 Priority Review Vouchers from the FDA. Biostage’s current goals include raising capital, uplisting from the OTC bulletin board to NASDAQ and beginning its clinical trial for regeneration and repair of the esophagus.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Harvard Apparatus Regenerative Technology, Inc.’s Item 2.02 8-K filed November 14, 2022; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.